The Wall Street Journal reported on the booming longevity industry and the regulatory challenges faced by companies marketing NMN supplements. The article highlights the dispute between supplement companies and pharmaceutical firms over NMN’s classification and the FDA’s stance on its legality as a dietary supplement.